Known targets — ChEMBL curated mechanism
ABL1BMXBRAFBTKCHRNA4CHRNB2CSNK1EEGFRERBB2F10FLT1FLT3FLT4IGF1RINSRITKJAK3KDRKITOPRM1PARP1PARP2PDGFRBPIK3CDRAF1RETSLC18A2TECTXKdacAdacBdacCftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Propionic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KEAP1 | Q14145 | 1/20 | 0.49 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | SNCA | P37840 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Malonic Acid SCHEMBL10920135 | 0.88 | KEAP1 (0.49) | KEAP1NFE2L2ALDH1A1SMN1; SMN2LMNA | |
| Glycolic Acid SCHEMBL8907068 | 0.88 | KEAP1 (0.49) | KEAP1NFE2L2ALDH1A1SMN1; SMN2LMNA | |
| Glycolic Acid SCHEMBL1872362 | 0.88 | KEAP1 (0.49) | KEAP1NFE2L2ALDH1A1SMN1; SMN2LMNA | |
| Bicarbonate SCHEMBL6755891 | 0.87 | SMN1; SMN2 (0.54) | KEAP1NFE2L2ALDH1A1SMN1; SMN2LMNA | |
| Propane SCHEMBL28408609 | 0.87 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAKDM4EMAPT | |
| Propane SCHEMBL3563886 | 0.87 | GAA (0.54) | ALDH1A1SMN1; SMN2LMNAKDM4EMAPT | |
| Hydrogen Peroxide SCHEMBL29268503 | 0.87 | SMN1; SMN2 (0.59) | ALDH1A1SMN1; SMN2LMNAKDM4EMAPT | |
| Butyric Acid SCHEMBL9690701 | 0.87 | KMT2A (0.47) | KEAP1NFE2L2ALDH1A1SMN1; SMN2LMNA | |
| Propionamide SCHEMBL9545062 | 0.86 | ALDH1A1 (0.59) | ALDH1A1SMN1; SMN2LMNAKDM4EMAPT | |
| Succinic Acid SCHEMBL11462893 | 0.86 | KMT2A (0.53) | KEAP1NFE2L2ALDH1A1SMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111655680-B | Hormone receptor modulators for the treatment of metabolic mutations and fibrotic conditions and disorders | 阿德利克斯股份有限公司 | 2024-03-05 | — | — | CN | disclosed |
| EP-4312987-A1 | COMPOSITIONS AND METHODS FOR TARGETED DELIVERY TO CELLS | Recode Therapeutics, Inc. (US) | 2024-02-07 | — | — | EP | disclosed |
| WO-2022073905-A1 | MRGX2 ANTAGONISTS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2022-04-14 | — | — | WO | disclosed |
| CN-113453724-A | Sulfonylmaleimide-based linkers and corresponding conjugates | 皮埃尔法布雷医药公司 | 2021-09-28 | — | — | CN | disclosed |
| EP-3104707-A1 | TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS | Albert Einstein College of Medicine, Inc. (US) | 2016-12-21 | — | — | EP | disclosed |
| WO-2015123101-A1 | TREATMENT OF H. PYLORI INFECTIONS USING MTAN INHIBITORS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2014179187-A1 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING ELECTROPHILE-MEDIATED TOXICITIES | MONTEFIORE MEDICAL CENTER (US) | 2014-11-06 | — | — | WO | disclosed |
| WO-2014025842-A1 | TREATMENT OF HELICOBACTER PYLORI INFECTIONS | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2014-02-13 | — | — | WO | disclosed |
| WO-2012074912-A1 | METHODS, ASSAYS AND COMPOUNDS FOR TREATING BACTERIAL INFECTIONS BY INHIBITING METHYLTHIOINOSINE PHOSPHORYLASE | ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (US) | 2012-06-07 | — | — | WO | disclosed |
| EP-1596869-A4 | NOVEL COCRYSTALLIZATION | S S C I INC (US) | 2007-04-25 | — | — | EP | disclosed |
| EP-1740930-A2 | SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND | S.S.C.I., Inc (US) | 2007-01-10 | — | — | EP | disclosed |
| WO-2004064762-A9 | NOVEL COCRYSTALLIZATION | S S C I INC (US) | 2006-07-27 | — | — | WO | disclosed |
| EP-1596869-A2 | NOVEL COCRYSTALLIZATION | S.S.C.I., Inc (US) | 2005-11-23 | — | — | EP | disclosed |
| WO-2005089375-A2 | SCREENING FOR SOLID FORMS BY ULTRASOUND CRYSTALLIZATION AND COCRYSTALLIZATION USING ULTRASOUND | S.S.C.I., INC. (US) | 2005-09-29 | — | — | WO | disclosed |
| WO-2004064762-A2 | NOVEL COCRYSTALLIZATION | S.S.C.I. INC. (US) | 2004-08-05 | — | — | WO | disclosed |
| US-4943514-A | POLYMERIC MORDANT FROM QUATERNIZED VINYLIMIDAZOLE | EASTMAN KODAK COMPANY (US) | 1990-07-24 | — | — | US | disclosed |
| US-4942103-A | POLYVINYL ALCOHOL BINDERS, RADIATION SENSITIVE DICHROMATES, A POLYMERIC MORDANT OF QUATERNIZED N-VINYLIMIDAZOLES | EASTMAN KODAK COMPANY (US) | 1990-07-17 | — | — | US | disclosed |